<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: Additional ", fill: "#708090"},
{source: "3: Additional ", target: "3: immaterial may also impair", fill: "#708090"},
{source: "3: immaterial may also impair", target: "3: operations", fill: "#708090"},
{source: "3: Additional ", target: "5: trading price", fill: "#c80815"},
{source: "5: trading price", target: "5: common stock could decline", fill: "#c80815"},
{source: "5: common stock could decline", target: "5: impaired due", fill: "#c80815"},
{source: "5: impaired due", target: "5: investors may lose", fill: "#c80815"},
{source: "5: investors may lose", target: "5: investment", fill: "#c80815"},
{source: "5: trading price", target: "6: risks investors should also", fill: "#0d98ba"},
{source: "6: risks investors should also", target: "6: incorporated by reference", fill: "#0d98ba"},
{source: "6: incorporated by reference", target: "6: Annual Report ", fill: "#0d98ba"},
{source: "6: Annual Report ", target: "6: consolidated financial", fill: "#0d98ba"},
{source: "6: risks investors should also", target: "7: developmental stage", fill: "#654321"},
{source: "7: developmental stage", target: "7: regulatory approval", fill: "#654321"},
{source: "7: regulatory approval", target: "7: become commercially", fill: "#654321"},
{source: "7: developmental stage", target: "8: immunotherapies", fill: "#da2c43"},
{source: "8: immunotherapies", target: "8: development", fill: "#da2c43"},
{source: "8: immunotherapies", target: "11: products currently under development will", fill: "#f3e5ab"},
{source: "11: products currently under development will", target: "11: significant additional", fill: "#f3e5ab"},
{source: "11: significant additional", target: "11: development efforts", fill: "#f3e5ab"},
{source: "11: development efforts", target: "11: clinical testing", fill: "#f3e5ab"},
{source: "11: clinical testing", target: "11: regulatory approval prior", fill: "#f3e5ab"},
{source: "11: regulatory approval prior", target: "11: commercial use", fill: "#f3e5ab"},
{source: "11: products currently under development will", target: "17: trials may", fill: "#a76bcf"},
{source: "17: trials may", target: "17: safety issues", fill: "#a76bcf"},
{source: "17: safety issues", target: "17: investigators", fill: "#a76bcf"},
{source: "17: investigators", target: "17: comply with", fill: "#a76bcf"},
{source: "17: comply with", target: "17: regulations governing clinical trials", fill: "#a76bcf"},
{source: "17: trials may", target: "18: proposed products", fill: "#92000a"},
{source: "18: proposed products", target: "18: regulatory authorities", fill: "#92000a"},
{source: "18: regulatory authorities", target: "18: Institutional Review Boards ", fill: "#92000a"},
{source: "18: Institutional Review Boards ", target: "18: institutions will", fill: "#92000a"},
{source: "18: institutions will", target: "18: clinical trials", fill: "#92000a"},
{source: "18: clinical trials", target: "18: human clinical trials", fill: "#92000a"},
{source: "18: human clinical trials", target: "18: adequate numbers", fill: "#92000a"},
{source: "18: proposed products", target: "41: accumulated deficit would", fill: "#30d5c8"},
{source: "41: accumulated deficit would", target: "41: substantially higher absent", fill: "#30d5c8"},
{source: "41: substantially higher absent", target: "41: common stock", fill: "#30d5c8"},
{source: "41: accumulated deficit would", target: "START_HERE", fill: "#30d5c8"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Ask for protection</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_Trials_Directive">Clinical Trials Directive</a></td>
      <td>The Clinical Trials Directive (Officially Directive 2001/20/EC of 4 April 2001, of the European Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the Member States relating to implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use) is a European Union directive that aimed at facilitating the internal market in medicinal products within the European Union, while at the same time maintaining an appropriate level of protection for public health. It seeks to simplify and harmonise the administrative provisions governing clinical trials in the European Community, by establishing a clear, transparent procedure.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Analysis_of_clinical_trials">Analysis of clinical trials</a></td>
      <td>The analysis of clinical trials involves many related topics including:\n\nthe choice of an estimand (measure of effect size) of interest that is closely linked to the objectives of the trial,\nthe choice and definition of analysis sets,\nthe choice of an appropriate statistical model for the type of data being studied,\nappropriate accounting for the treatment assignment process,\nhandling of missing data,\nhandling of multiple comparisons or endpoints,\naccounting for interim analyses and trial adaptations,\nand appropriate data presentation.One basic guidance document on this topic is the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guidance E9.\n\n\n== Choice of analysis set ==\nFailure to include all participants in the analysis may bias the trial results.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Class_B_share">Class B share</a></td>
      <td>In finance, a Class B share or Class C share is a designation for a share class of a common or preferred stock that typically has strengthened voting rights or other benefits compared to a Class A share that may have been created. The equity structure, or how many types of shares are offered, is determined by the corporate charter.B share can also refer to various terms relating to stock classes:\n\nB share (mainland China), a class of stock on the Shanghai and Shenzhen stock exchanges\nB share (NYSE), a class of stock on the New York Stock ExchangeMost of the time, Class B shares may have lower repayment priorities in the event a company declares bankruptcy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CELL GENESYS INC      ITEM 1A RISK FACTORS             Investors <font color="blue">should carefully</font> consider the <font color="blue">risks described</font> below before     making an <font color="blue"><font color="blue">investment</font> decision</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">risks described</font> below are not the only     ones facing our company</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks not currently known to us or that     we currently believe are <font color="blue">immaterial may also impair</font> our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our business could be <font color="blue">harmed by</font> any of these risks</td>
    </tr>
    <tr>
      <td>The <font color="blue">trading price</font> of our     <font color="blue"><font color="blue">common stock</font> could decline</font>, and our ability to repay our convertible notes     could be impaired, due to any of these risks, and <font color="blue">investors may lose</font> all or     part of their <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>In assessing these risks, investors should also     refer to the other information contained or <font color="blue">incorporated by reference</font> in     this  <font color="blue">Annual Report </font>on Form 10-K, including our <font color="blue">consolidated financial</font>     statements and related notes</td>
    </tr>
    <tr>
      <td>Risks Related to Our Company       Our products are in <font color="blue"><font color="blue">development</font>al stage</font>, are not approved for commercial     sale and might not ever receive <font color="blue"><font color="blue">regulatory</font> approval</font> or <font color="blue">become <font color="blue">commercially</font></font>     viable</td>
    </tr>
    <tr>
      <td>All of our potential cancer <font color="blue">immunotherapies</font> and oncolytic virus     therapies  are  in research and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We do not expect to generate any     revenues  from  <font color="blue">product sales</font> for at least the <font color="blue">next <font color="blue">several years</font></font></td>
    </tr>
    <tr>
      <td>Our     products currently under <font color="blue">development</font> will require <font color="blue"><font color="blue">significant</font> <font color="blue">additional</font></font>     research  and <font color="blue">development</font> efforts, including extensive preclinical and     <font color="blue">clinical testing</font> and <font color="blue"><font color="blue">regulatory</font> approval</font>, prior to <font color="blue">commercial use</font></td>
    </tr>
    <tr>
      <td>Our     research and <font color="blue">development</font> efforts may not be successful, and any of our     <font color="blue"><font color="blue">future products</font> may</font> not be <font color="blue">ultimately <font color="blue">commercially</font> successful</font></td>
    </tr>
    <tr>
      <td>Even if     developed,  our  products  may  not  receive <font color="blue"><font color="blue">regulatory</font> approval</font> or be     <font color="blue"><font color="blue">successfully</font> introduced</font> and <font color="blue">marketed at prices</font> that <font color="blue">would permit us</font> to     operate profitably</td>
    </tr>
    <tr>
      <td>Our cancer <font color="blue">immunotherapies</font> and <font color="blue"><font color="blue">oncolytic <font color="blue">virus therapies</font></font> <font color="blue">must undergo</font></font>     exhaustive <font color="blue">clinical testing</font> and may not prove to be safe or <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>If     any of our <font color="blue">proposed products</font> are delayed or fail, we may have to curtail our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>There are many reasons that <font color="blue">potential products</font> that appear promising     at an <font color="blue">early stage</font> of research or <font color="blue">development</font> do not result in <font color="blue">commercially</font>     <font color="blue">successful products</font></td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">trials may</font> be suspended or terminated if     <font color="blue">safety issues</font> are identified, if our <font color="blue">investigators</font> or we fail to <font color="blue">comply with</font>     <font color="blue"><font color="blue">regulations</font> governing <font color="blue"><font color="blue">clinical trial</font>s</font></font> or for other reasons</td>
    </tr>
    <tr>
      <td>Although we and     our <font color="blue">investigators</font> are testing some of our <font color="blue">proposed products</font> and therapies in     human  clinical  trials, we <font color="blue">cannot guarantee</font> that we, the FDA, foreign     <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font> or the <font color="blue">Institutional Review Boards </font>at our research     <font color="blue"><font color="blue">institutions</font> will</font> not suspend or terminate any of our <font color="blue"><font color="blue">clinical trial</font>s</font>, that     we will be permitted to undertake human <font color="blue"><font color="blue">clinical trial</font>s</font> for any of our     products or that <font color="blue">adequate numbers</font> of patients can be recruited for our     <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Also, the results of this testing might not <font color="blue">demonstrate</font> the     safety  or  efficacy  of  these  products</td>
    </tr>
    <tr>
      <td>Even if <font color="blue"><font color="blue">clinical trial</font>s</font> are     successful, we might not obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for any <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td><font color="blue">Preclinical </font>and <font color="blue">clinical data</font> can be interpreted in many <font color="blue">different</font> ways, and     FDA or foreign <font color="blue">regulatory</font> officials could interpret data that we consider     promising <font color="blue">different</font>ly, <font color="blue">which could</font> halt or delay our <font color="blue"><font color="blue">clinical trial</font>s</font> or     prevent  <font color="blue">regulatory</font>  approval</td>
    </tr>
    <tr>
      <td>Finally,  even if our <font color="blue">products proceed</font>     <font color="blue">successfully</font> through <font color="blue"><font color="blue">clinical trial</font>s</font> and receive <font color="blue"><font color="blue">regulatory</font> approval</font>, there     is no guarantee that an <font color="blue">approved product</font> can be <font color="blue"><font color="blue">manufacture</font>d</font> in commercial     <font color="blue">quantities at reasonable cost</font> or that such a <font color="blue">product will</font> be <font color="blue">successfully</font>     marketed</td>
    </tr>
    <tr>
      <td>Our <font color="blue">programs utilize new <font color="blue">technologies</font></font></td>
    </tr>
    <tr>
      <td>Existing preclinical and     <font color="blue"><font color="blue">clinical data</font> on</font> the safety and efficacy of our programs are limited</td>
    </tr>
    <tr>
      <td>Our     GVAX cancer <font color="blue">immunotherapies</font> and <font color="blue">oncolytic <font color="blue">virus therapies</font></font> are currently     being  tested  in  human <font color="blue"><font color="blue">clinical trial</font>s</font> to determine their safety and     efficacy</td>
    </tr>
    <tr>
      <td>The results of preclinical or earlier stage <font color="blue"><font color="blue">clinical trial</font>s</font> do not     <font color="blue">necessarily predict safety</font> or efficacy in humans</td>
    </tr>
    <tr>
      <td>Our products in later     stage clinical <font color="blue">trials may</font> fail to show desired safety and efficacy, despite     having progressed <font color="blue">through preclinical</font> or early <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Serious and     <font color="blue">potentially</font>  life-threatening  side  effects  may be discovered during     preclinical and <font color="blue">clinical testing</font> of our <font color="blue">potential products</font> or thereafter,     <font color="blue">which could</font> delay, halt or interrupt <font color="blue"><font color="blue">clinical trial</font>s</font> of our products, and     could result <font color="blue">in the FDA </font>or other <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font> denying approval of     our drugs for any or all <font color="blue">indication</font>s</td>
    </tr>
    <tr>
      <td>Clinical trials are very costly and time-consuming, especially the     <font color="blue">typically larger</font> Phase 3 <font color="blue"><font color="blue">clinical trial</font>s</font> such as the VITAL-1 and VITAL-2     trials  of our GVAX <font color="blue">immunotherapy</font> for <font color="blue">prostate cancer</font></td>
    </tr>
    <tr>
      <td>The VITAL-1 and     VITAL-2 trials of our GVAX <font color="blue">immunotherapy</font> for <font color="blue">prostate cancer</font> are our first     Phase 3 <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">We                                         </font>15       _________________________________________________________________    [68]Table of <font color="blue">Contents       </font><font color="blue">cannot exactly predict</font> if and when any of our current <font color="blue"><font color="blue">clinical trial</font>s</font> will     be completed</td>
    </tr>
    <tr>
      <td>Many <font color="blue">factors affect <font color="blue">patient enrollment</font></font> in <font color="blue"><font color="blue">clinical trial</font>s</font>,     including the size of the <font color="blue">patient population</font>, the proximity of patients to     <font color="blue">clinical sites</font>, the <font color="blue">eligibility criteria</font> for the trial, competing clinical     trials  and  new  therapies  approved  for  the <font color="blue">conditions</font> that we are     <font color="blue">investigating</font></td>
    </tr>
    <tr>
      <td>In addition to delays in <font color="blue">patient enrollment</font>, other unforeseen     <font color="blue">development</font>s, including delays in obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s to commence     a study, delays in identifying and <font color="blue">reaching agreement on</font> acceptable terms     with prospective <font color="blue">clinical trial</font> sites, lack of <font color="blue">effective</font>ness during clinical     trials, unforeseen <font color="blue">safety issues</font>, uncertain dosing issues, <font color="blue">inability</font> to     monitor  patients  <font color="blue">adequately</font>  during  or  after treatment, our or our     <font color="blue">investigators</font>’  failure  to  <font color="blue">comply with</font> FDA or other <font color="blue">health authority</font>     <font color="blue"><font color="blue">regulations</font> governing <font color="blue"><font color="blue">clinical trial</font>s</font></font>, and an <font color="blue">inability</font> or <font color="blue">un<font color="blue">willingness</font></font> of     medical <font color="blue">investigators</font> to follow our clinical protocols, <font color="blue">could prevent</font> or     <font color="blue">delay <font color="blue">completion</font></font> of a <font color="blue">clinical trial</font> and increase its costs, <font color="blue">which could</font>     <font color="blue">also prevent</font> or delay any <font color="blue">eventual commercial sale</font> of the therapy that is     the subject of the trial</td>
    </tr>
    <tr>
      <td>Each of our two Phase 3 <font color="blue"><font color="blue">clinical trial</font>s</font> of GVAX     <font color="blue">immunotherapy</font>  for <font color="blue">prostate cancer</font> involves a <font color="blue">comparison</font> to a <font color="blue">Taxotere     </font><font color="blue">chemotherapy</font> regimen, which is the <font color="blue">currently approved</font> standard of care for     this  patient  group</td>
    </tr>
    <tr>
      <td>However,  there  can  be no assurance that this     <font color="blue">chemotherapy</font>  <font color="blue">regimen <font color="blue">will continue</font></font> to be <font color="blue">commonly used</font> to treat these     patients in the future</td>
    </tr>
    <tr>
      <td>Should another <font color="blue">chemotherapy</font> regimen be shown to be     more  <font color="blue">effective</font> than <font color="blue">the Taxotere </font><font color="blue">chemotherapy</font> regimen, we may need to     conduct <font color="blue">additional</font> comparative <font color="blue"><font color="blue">clinical trial</font>s</font> in the future</td>
    </tr>
    <tr>
      <td>We have not <font color="blue">been profitable absent</font> the <font color="blue">gains on sales</font> of Abgenix common     stock and <font color="blue">certain upfront</font> or non-recurring license fees</td>
    </tr>
    <tr>
      <td>We expect to     continue to incur substantial losses and negative <font color="blue">cash flow</font> from <font color="blue">operations</font>     and may not <font color="blue">become profitable</font> in the future</td>
    </tr>
    <tr>
      <td>We have incurred an <font color="blue"><font color="blue">accumulated</font> deficit since</font> our inception</td>
    </tr>
    <tr>
      <td>At     <font color="blue">December </font>31,  2005,  our  <font color="blue">accumulated</font>  deficit was dlra308dtta9 million</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">accumulated</font> deficit would be <font color="blue"><font color="blue">substantially</font> higher absent</font> the gains we have     realized  on  sales  of  our  Abgenix <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>For the year ended     <font color="blue">December </font>31, 2005, we recorded a net loss of dlra64dtta9 million</td>
    </tr>
    <tr>
      <td>We expect to     incur substantial operating losses for at least the <font color="blue">next <font color="blue">several years</font></font> and     <font color="blue"><font color="blue">potentially</font> longer</font></td>
    </tr>
    <tr>
      <td>This is <font color="blue">due primarily</font> to the expansion of <font color="blue">development</font>     programs, <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue"><font color="blue">manufacturing</font> <font color="blue">activities</font></font> and, to a lesser     extent, general and <font color="blue">administrative</font> expenses, at a time when we have yet to     realize any <font color="blue">product revenues</font></td>
    </tr>
    <tr>
      <td>We also have substantial <font color="blue">lease <font color="blue">obligations</font></font>     related to our <font color="blue">manufacturing</font> and <font color="blue">headquarter <font color="blue">facilities</font></font></td>
    </tr>
    <tr>
      <td>We expect that     <font color="blue">losses will fluctuate from quarter</font> to quarter and that these <font color="blue">fluctuations</font>     may be substantial</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that we will <font color="blue">successfully</font> develop,     <font color="blue">manufacture</font>, <font color="blue">commercialize</font> or market any products, or that we will ever     achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We will need substantial <font color="blue"><font color="blue">additional</font> funds</font> to continue <font color="blue">operations</font>, and our     ability to <font color="blue">generate funds depends on</font> many <font color="blue">factors beyond</font> our control</td>
    </tr>
    <tr>
      <td>We will need substantial <font color="blue"><font color="blue">additional</font> funds</font> for existing and planned     preclinical  and <font color="blue"><font color="blue">clinical trial</font>s</font>, to <font color="blue">continue research</font> and <font color="blue">development</font>     <font color="blue">activities</font>,  for  lease  <font color="blue">obligations</font>  related to our <font color="blue">manufacturing</font> and     <font color="blue">headquarter <font color="blue">facilities</font></font>, for principal and <font color="blue">interest payments</font> related to our     debt financing <font color="blue">obligations</font>, for <font color="blue">potential settlements</font> to the IRS and other     <font color="blue">tax <font color="blue">authorities</font></font> and to <font color="blue">establish <font color="blue">marketing capabilities</font></font> for any products we     may  develop</td>
    </tr>
    <tr>
      <td>At some point in the future, we will also need to raise     <font color="blue"><font color="blue">additional</font> capital</font> to <font color="blue">further fund</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In July 2005, the IRS issued to us a Notice of Proposed Adjustment     (“NOPA”) seeking to disallow dlra48dtta7 million of net operating <font color="blue">losses which</font> we     deducted for the 2000 fiscal year and seeking a dlra3dtta4 million penalty for     substantial <font color="blue">underpayment</font> of tax in fiscal 2000</td>
    </tr>
    <tr>
      <td>We responded to the NOPA in     <font color="blue">September </font>2005, disagreeing with the <font color="blue">conclusions reached by</font> the IRS in the     NOPA  and  seeking to resolve this matter at <font color="blue">the Appeals </font>level</td>
    </tr>
    <tr>
      <td>We had     <font color="blue">previously recorded</font> a <font color="blue">liability</font> for this and other federal and state tax     <font color="blue">contingencies</font>, including estimated <font color="blue">interest expense</font></td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font>     in defending the <font color="blue">tax filing positions</font> that we have previously taken, then     <font color="blue">potentially</font> our <font color="blue">liability</font> for federal and state tax <font color="blue">contingencies</font> could be     <font color="blue"><font color="blue">significant</font>ly higher than</font> the dlra32dtta6 million that we have <font color="blue">recorded as</font> of     <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>We continue to believe that our tax positions <font color="blue">comply with</font>     all <font color="blue">applicable tax laws</font>, and we continue to <font color="blue">vigorously defend against</font> the     NOPA using all <font color="blue">administrative</font> and <font color="blue">legal processes available</font> to us</td>
    </tr>
    <tr>
      <td>16       _________________________________________________________________    [69]Table of <font color="blue">Contents       </font>      Our <font color="blue">future capital <font color="blue"><font color="blue">requirement</font>s</font> will <font color="blue">depend on</font></font>, and <font color="blue">could increase as</font>     a result of, many factors, such as:         •  the progress and scope of our internally funded research, <font color="blue">development</font>,     clinical, <font color="blue">manufacturing</font> and <font color="blue">commercialization</font> <font color="blue">activities</font>;         •  our ability to <font color="blue">establish new <font color="blue">collaborations</font></font> and the terms of those     <font color="blue">collaborations</font>;         •  our ability to reach a favorable <font color="blue">resolution with</font> the IRS <font color="blue">with respect</font>     to their audit of our fiscal 2000 federal tax return, or to other potential     <font color="blue">tax assessments</font>;         •  <font color="blue">competing technological</font> and market <font color="blue">development</font>s;         •  the time and cost of <font color="blue"><font color="blue">regulatory</font> approval</font>s;         •  the extent to which we choose to <font color="blue">commercialize</font> our <font color="blue">future products</font>     through our own sales and <font color="blue">marketing capabilities</font>;         •  the costs we incur in obtaining, defending and <font color="blue">enforcing patent</font> and     other <font color="blue"><font color="blue">proprietary</font> rights</font> or gaining the freedom to operate under the patents     of others;          •  our success in acquiring and <font color="blue"><font color="blue">integrating</font> complementary products</font>,     <font color="blue">technologies</font> or <font color="blue">businesses</font>; and         •  the extent to which we choose to expand and develop our <font color="blue">manufacturing</font>     <font color="blue">capacities</font>, including <font color="blue">manufacturing</font> <font color="blue">capacities</font> <font color="blue">necessary</font> to <font color="blue">meet potential</font>     <font color="blue">commercial <font color="blue"><font color="blue">requirement</font>s</font></font></td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are not available, we may be required to delay,     reduce the scope of, or <font color="blue">eliminate one</font> or more of our research, <font color="blue">development</font>,     <font color="blue">manufacturing</font> or clinical <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We plan to raise <font color="blue"><font color="blue">additional</font> funds</font> through collaborative business     <font color="blue">relationships</font>, <font color="blue"><font color="blue">additional</font> equity</font> or <font color="blue">debt <font color="blue">financings</font></font>, or otherwise, but we     may not be able to do any of the <font color="blue">foregoing on</font> favorable terms, or at all</td>
    </tr>
    <tr>
      <td>Because of our long-term capital <font color="blue"><font color="blue">requirement</font>s</font>, we may seek to access     the public or private debt and equity markets and/or sell our own debt or     <font color="blue">equity securities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">funding may</font> not be available to us, and, if     available, may not be on acceptable terms</td>
    </tr>
    <tr>
      <td><font color="blue">Opportunities </font>for <font color="blue">outlicensing</font>     <font color="blue">technologies</font> or for third-party <font color="blue">collaborations</font> may not be available to us on     acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are not available, we may be     required to delay, reduce the scope of, or <font color="blue">eliminate one</font> or more of our     research, <font color="blue">development</font>, <font color="blue">manufacturing</font> or clinical <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>In addition, we     may decide to raise <font color="blue"><font color="blue">additional</font> capital</font> when <font color="blue">conditions</font> are favorable, even     when we do not have an immediate need for <font color="blue"><font color="blue">additional</font> capital</font> at that time</td>
    </tr>
    <tr>
      <td>If we raise <font color="blue"><font color="blue">additional</font> funds</font> by issuing <font color="blue">equity securities</font>, <font color="blue">stockholders</font> will     <font color="blue">incur immediate dilution</font></td>
    </tr>
    <tr>
      <td>Alternatively, we may need to <font color="blue">seek funds through <font color="blue">arrangements</font> with</font>     <font color="blue">collaborative partners</font> or others that require us to <font color="blue">relinquish rights</font> to     <font color="blue">technologies</font> or <font color="blue">product candidates</font> that we <font color="blue">would otherwise seek</font> to develop     or <font color="blue">commercialize</font> ourselves</td>
    </tr>
    <tr>
      <td>Either of these events could have a material     adverse effect on our business, results of <font color="blue">operations</font>, <font color="blue">financial condition</font>     or <font color="blue">cash flow</font></td>
    </tr>
    <tr>
      <td>Currently, we do not have <font color="blue">collaborative partners</font> for the     further <font color="blue">development</font> of our GVAX cancer <font color="blue">immunotherapies</font></td>
    </tr>
    <tr>
      <td>Although we are in     <font color="blue">active discussions with potential partners</font> for our GVAX <font color="blue">immunotherapy</font> for     <font color="blue">prostate cancer</font>, we may not be successful in <font color="blue">entering into collaborative</font>     <font color="blue">partnerships on</font> favorable terms, if at all</td>
    </tr>
    <tr>
      <td>Certain of our oncolytic virus     therapy products are being developed under our global strategic alliance     with Novartis, and Novartis has <font color="blue">future <font color="blue">commercialization</font> rights</font> for these     products</td>
    </tr>
    <tr>
      <td>Also, we can <font color="blue">give no assurance</font> that our <font color="blue">alliance with</font> Novartis     <font color="blue">will continue</font>, as Novartis <font color="blue">periodically</font> has the option of <font color="blue">terminating</font> the     <font color="blue">alliance at</font> its <font color="blue">discretion</font></td>
    </tr>
    <tr>
      <td>We announced in 2005 the <font color="blue">development</font> of a novel     <font color="blue">technology</font> for the production of <font color="blue">monoclonal antibody products which</font> is     outside  our  core business focus and <font color="blue">which therefore may represent</font> an     <font color="blue">outlicensing</font>  <font color="blue">opportunity</font></td>
    </tr>
    <tr>
      <td>There  can be no assurance that we will be     successful  in  our efforts to raise capital through such <font color="blue">outlicensing</font>     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Failure to enter into new corporate <font color="blue">relationships</font> may limit our     future success</td>
    </tr>
    <tr>
      <td>17       _________________________________________________________________    [70]Table of <font color="blue">Contents       </font>We plan to <font color="blue">use potential future</font> operating losses and our federal and state     net operating <font color="blue">loss <font color="blue">carryforwards</font></font> to <font color="blue">offset taxable <font color="blue">income from</font> revenue</font>     generated from <font color="blue">operations</font> or from the sale of Abgenix <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>However,     our ability to use net operating <font color="blue">loss <font color="blue">carryforwards</font></font> could be limited as a     result of <font color="blue">potential future issuances</font> of <font color="blue">equity securities</font></td>
    </tr>
    <tr>
      <td>We plan to use our <font color="blue">current year</font> operating losses to offset taxable     <font color="blue">income from</font> any revenue generated from <font color="blue">operations</font>, corporate <font color="blue">collaborations</font>     or from the sale of Abgenix <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>To the extent that our taxable     income exceeds any <font color="blue">current year</font> operating losses, we plan to use our net     operating  <font color="blue">loss <font color="blue">carryforwards</font></font> to offset income that would otherwise be     taxable</td>
    </tr>
    <tr>
      <td>However, our use of <font color="blue">federal net</font> operating <font color="blue">loss <font color="blue">carryforwards</font></font> could     be limited in the future by the provisions of Section 382 of the Internal     Revenue Code <font color="blue">depending upon</font> the timing and amount of <font color="blue"><font color="blue">additional</font> equity</font>     securities  that  we might <font color="blue">potentially</font> issue</td>
    </tr>
    <tr>
      <td>State net operating loss     <font color="blue">carryforwards</font> may be similarly limited</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">manufacture</font> our products is uncertain, which may delay or     impair our ability to develop, test and <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>We have built our own <font color="blue">manufacturing</font> <font color="blue">facility</font> to operate <font color="blue">according</font> to     the FDA’s current <font color="blue">Good Manufacturing Practices </font>(cGMP) <font color="blue">regulations</font> for the     <font color="blue">manufacture</font> of products for <font color="blue"><font color="blue">clinical trial</font>s</font> and to support the potential     <font color="blue">commercial launch</font> of our GVAX cancer <font color="blue">immunotherapy</font> <font color="blue">product candidates</font></td>
    </tr>
    <tr>
      <td>We     are under <font color="blue">significant</font> <font color="blue">lease <font color="blue">obligations</font></font> for our <font color="blue">manufacturing</font> <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>We     may be unable to establish and maintain our <font color="blue">manufacturing</font> <font color="blue">facility</font> for     <font color="blue">increased scale within</font> our planned timelines and budget, <font color="blue">which could</font> have a     material  adverse  effect  on  our  product <font color="blue">development</font> timelines</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">manufacturing</font> <font color="blue">facility</font> will be subject to ongoing, periodic <font color="blue">inspection by</font>     the FDA and other <font color="blue">regulatory</font> bodies to <font color="blue">ensure compliance with cGMP</font> Our     failure to follow and document our adherence to such <font color="blue">cGMP <font color="blue">regulations</font></font> or     other  <font color="blue">regulatory</font>  <font color="blue"><font color="blue">requirement</font>s</font>  may lead to <font color="blue"><font color="blue">significant</font> delays</font> in the     <font color="blue">availability</font> of products for <font color="blue">commercial use</font> or <font color="blue">clinical study</font>, may result in     the <font color="blue">termination</font> or hold on a <font color="blue">clinical study</font>, or may delay or <font color="blue">prevent filing</font>     or  approval  of  <font color="blue">marketing <font color="blue"><font color="blue">application</font>s</font></font> for our products</td>
    </tr>
    <tr>
      <td>We also may     <font color="blue">encounter problems with</font> the following:         •  achieving <font color="blue">consistent</font> and acceptable <font color="blue">production yield</font> and costs;         •  <font color="blue">meeting <font color="blue">product release specifications</font></font>;         •  shortages of <font color="blue">qualified personnel</font>;         •  shortages of <font color="blue">raw materials</font>;         •  shortages of <font color="blue">key contractors</font> or contract <font color="blue">manufacture</font>rs; and         •  ongoing compliance with <font color="blue">cGMP <font color="blue">regulations</font></font> and other <font color="blue">expectations from</font>     FDA and other <font color="blue">regulatory</font> bodies</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> applicable <font color="blue">regulations</font> could also result in     sanctions  being  imposed  on  us, including fines, <font color="blue">injunctions</font>, civil     penalties, failure of <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font> to grant marketing approval of     our  products,  delays, suspension or withdrawal of approvals, license     revocation, seizures or recalls of products, operating <font color="blue">restrictions</font> and     criminal <font color="blue">prosecutions</font>, any of <font color="blue"><font color="blue">which could</font> harm</font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">Developing </font>advanced <font color="blue">manufacturing</font> <font color="blue">techniques</font> and <font color="blue">process controls</font> is     required to <font color="blue">fully utilize</font> our <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacturing</font> <font color="blue">techniques</font> and     <font color="blue">process controls</font>, as well as the <font color="blue">product release specifications</font>, required     for our GVAX cancer <font color="blue">immunotherapies</font> and <font color="blue">oncolytic <font color="blue">virus therapies</font></font> are more     complex  and  less  well-established  than  those  required  for other     <font color="blue">bio<font color="blue"><font color="blue">pharmaceutical</font> products</font></font>, including small molecules, therapeutic proteins     and <font color="blue">monoclonal antibodies</font></td>
    </tr>
    <tr>
      <td>We may not be able to develop these <font color="blue">techniques</font>     and <font color="blue">process controls</font> to <font color="blue">manufacture</font> and evaluate our products <font color="blue">effective</font>ly to     meet the demands of <font color="blue">regulatory</font> agencies, <font color="blue">clinical testing</font> and commercial     production</td>
    </tr>
    <tr>
      <td><font color="blue">Advances </font>in <font color="blue">manufacturing</font> <font color="blue">techniques</font> may render our <font color="blue">facility</font> and     equipment inadequate or obsolete</td>
    </tr>
    <tr>
      <td>In addition, during the course of the <font color="blue">development</font> and testing of our     products, we may make and have made <font color="blue">improvements</font> to processes, <font color="blue">formulations</font>     or <font color="blue">manufacturing</font> methods or employ <font color="blue">different</font> <font color="blue">manufacturing</font> <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font>changes may be made to improve the product’s potential efficacy, make it     easier to                                         18       _________________________________________________________________    [71]Table of <font color="blue">Contents       </font><font color="blue">manufacture</font> at scale, reduce variability or the chance of <font color="blue">contamination</font> of     the product, or for other reasons</td>
    </tr>
    <tr>
      <td>As a result, certain of the products we     are  <font color="blue">currently testing</font> in <font color="blue"><font color="blue">clinical trial</font>s</font>, including our most advanced     products, are not identical to those used in previous <font color="blue"><font color="blue">clinical trial</font>s</font> from     which we have reported <font color="blue">clinical data</font></td>
    </tr>
    <tr>
      <td>We may be required to <font color="blue">conduct certain</font>     <font color="blue">laboratory studies</font> to <font color="blue">demonstrate</font> the <font color="blue">comparability</font> of our products if we     introduce <font color="blue">additional</font> <font color="blue">manufacturing</font> changes</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that the     results of <font color="blue">studies using</font> the <font color="blue">current versions</font> of our <font color="blue">products will</font> be as     <font color="blue">successful as</font> the results of earlier studies conducted using <font color="blue">different</font>     versions of our products</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">manufacture</font> our products for any reason, our     options for outsourcing <font color="blue">manufacturing</font> are currently limited</td>
    </tr>
    <tr>
      <td>We are unaware     of available contract <font color="blue">manufacturing</font> <font color="blue">facilities</font> on a <font color="blue">worldwide basis</font> in which     our GVAX <font color="blue">product candidates</font> can be <font color="blue"><font color="blue">manufacture</font>d</font> under <font color="blue">cGMP <font color="blue">regulations</font></font>, a     <font color="blue">requirement</font> for all <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td>It would take a substantial     period of time for a contract <font color="blue">manufacturing</font> <font color="blue">facility</font> that has not been     producing  our  <font color="blue">particular products</font> to begin producing <font color="blue">them under cGMP</font>     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">manufacturing</font> <font color="blue">facility</font> is subject to the licensing <font color="blue"><font color="blue">requirement</font>s</font> of     the <font color="blue">United States </font>Drug Enforcement Administration (DEA), the <font color="blue">California </font>    Department of Health Services and foreign <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font></td>
    </tr>
    <tr>
      <td>While not     yet subject to <font color="blue">license by</font> the FDA, our <font color="blue">facility</font> is subject to <font color="blue">inspection by</font>     the FDA, <font color="blue">as well as by</font> the DEA and the <font color="blue">California </font>Department of Health     Services</td>
    </tr>
    <tr>
      <td>Failure to obtain or maintain these licenses or to meet the     inspection  criteria of these <font color="blue">agencies would disrupt</font> our <font color="blue">manufacturing</font>     processes and have a material adverse effect on our business, results of     <font color="blue">operations</font>, <font color="blue">financial condition</font> and <font color="blue">cash flow</font></td>
    </tr>
    <tr>
      <td>In order to produce our products in the quantities that we believe     will  be  required  to meet anticipated <font color="blue">market demand</font>, we will need to     increase, or “scale up,” the production process by a <font color="blue">significant</font> factor over     the <font color="blue">current level</font> of production</td>
    </tr>
    <tr>
      <td>If we are unable to do so, are delayed, or     if the cost of this scale up is not <font color="blue">economically feasible</font> for us, we may not     be  able  to produce our products in a <font color="blue">sufficient quantity</font> to meet the     <font color="blue"><font color="blue">requirement</font>s</font> for <font color="blue">product launch</font> or <font color="blue">future demand</font></td>
    </tr>
    <tr>
      <td><font color="blue">Logistical </font><font color="blue">arrangements</font>     for wide-spread <font color="blue">distribution</font> of our products for clinical and commercial     <font color="blue">purposes may prove</font> to be impractical or <font color="blue">prohibitively expensive <font color="blue">which could</font></font>     hinder our ability to <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> <font color="blue">clinical trial</font> <font color="blue">arrangements</font> with public and <font color="blue">private medical</font>     <font color="blue">institutions</font> to advance our <font color="blue">technology</font>, and the loss of these <font color="blue">arrangements</font>     <font color="blue">could impair</font> the <font color="blue">development</font> of our products</td>
    </tr>
    <tr>
      <td>We have <font color="blue">arrangements</font> with a number of public and <font color="blue">private medical</font>     <font color="blue">institutions</font>,  and  individual <font color="blue">investigators</font>, for the conduct of human     <font color="blue"><font color="blue">clinical trial</font>s</font> for our GVAX cancer <font color="blue">immunotherapy</font> programs and oncolytic     <font color="blue">virus therapies</font></td>
    </tr>
    <tr>
      <td>In some cases, <font color="blue">trials may</font> be conducted by <font color="blue">institutions</font>     without our <font color="blue">direct control</font> or monitoring</td>
    </tr>
    <tr>
      <td>The early <font color="blue">termination</font> of any of     these <font color="blue">clinical trial</font> <font color="blue">arrangements</font>, the failure of these <font color="blue">institutions</font> to     <font color="blue">comply with</font> the <font color="blue">regulations</font> and <font color="blue"><font color="blue">requirement</font>s</font> governing <font color="blue"><font color="blue">clinical trial</font>s</font>, or     <font color="blue">reliance upon</font> results of trials that we have not <font color="blue">directly conducted</font> or     <font color="blue">monitored could hinder</font> the progress of our <font color="blue">clinical trial</font> programs or our     <font color="blue">development</font> decisions</td>
    </tr>
    <tr>
      <td>If any of these <font color="blue">relationships</font> are terminated, the     clinical  trials  might not be completed, and the results might not be     evaluable</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> foreign <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> governing human     <font color="blue"><font color="blue">clinical trial</font>s</font> and marketing approval for drugs and devices <font color="blue">could prevent</font>     us from conducting our <font color="blue"><font color="blue">clinical trial</font>s</font> or selling our products in foreign     markets, which may <font color="blue">adversely</font> affect our operating results and financial     condition</td>
    </tr>
    <tr>
      <td>For <font color="blue">development</font> and marketing of drugs and <font color="blue">biologics outside</font> the     United States, the <font color="blue"><font color="blue">requirement</font>s</font> governing the conduct of <font color="blue"><font color="blue">clinical trial</font>s</font>,     product licensing, pricing and <font color="blue">reimbursement</font> vary greatly from country to     country  and  may  require us to perform <font color="blue">additional</font> testing and expend     <font color="blue">additional</font> resources</td>
    </tr>
    <tr>
      <td>The time required to obtain approvals outside the     <font color="blue">United States </font><font color="blue">may differ from</font> that required to obtain FDA approval</td>
    </tr>
    <tr>
      <td>We may     not  obtain foreign <font color="blue"><font color="blue">regulatory</font> approval</font>s on a <font color="blue">timely basis</font>, if at all</td>
    </tr>
    <tr>
      <td>Approval by the FDA does not ensure approval by <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font> in     other countries, and approval by one foreign <font color="blue">regulatory</font> authority does not     ensure approval by <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font> in other countries or by the FDA     Failure to <font color="blue">comply with</font> these <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> or obtain required     approvals <font color="blue">could impair</font> our ability to conduct <font color="blue"><font color="blue">clinical trial</font>s</font> in foreign     markets or <font color="blue">commercially</font> develop foreign markets for our products and may     have a material adverse effect on our results of <font color="blue">operations</font> and financial     condition</td>
    </tr>
    <tr>
      <td>19       _________________________________________________________________    [72]Table of <font color="blue">Contents       </font>If our <font color="blue">proposed products</font> are not <font color="blue">effective</font>ly protected by issued patents or     if we are not <font color="blue">otherwise able</font> to protect our <font color="blue">proprietary</font> information, we will     be more vulnerable to <font color="blue">competitors</font>, and our business could be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely heavily on</font> the <font color="blue">development</font> and protection of our <font color="blue">intellectual</font>     <font color="blue">property portfolio</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font>     firms, including ours, are <font color="blue"><font color="blue">generally</font> uncertain</font> and <font color="blue">involve <font color="blue">complex legal</font></font> and     factual questions</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had <font color="blue">approximately</font> 358 US     and foreign patents issued or granted to us or available to us <font color="blue">based on</font>     licensing <font color="blue">arrangements</font> and <font color="blue">approximately</font> 319 US and foreign <font color="blue"><font color="blue">application</font>s</font>     pending in our name or available to us <font color="blue">based on</font> licensing <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we are prosecuting patent <font color="blue"><font color="blue">application</font>s</font>, we cannot be certain     whether any <font color="blue">given <font color="blue">application</font> will</font> result in the issuance of a patent or, if     any  patent is issued, whether it will provide <font color="blue">significant</font> <font color="blue">proprietary</font>     protection or whether it will be invalidated</td>
    </tr>
    <tr>
      <td>Also, <font color="blue">depending upon</font> their     filing date, patent <font color="blue"><font color="blue">application</font>s</font> in the <font color="blue">United States </font>are <font color="blue"><font color="blue">confidential</font> until</font>     patents are published or issued</td>
    </tr>
    <tr>
      <td><font color="blue">Publication </font>of <font color="blue">discoveries</font> in scientific or     patent literature tends to lag behind actual <font color="blue">discoveries</font> by several months</td>
    </tr>
    <tr>
      <td>Accordingly, we cannot be sure that we were the first creator of <font color="blue">inventions</font>     covered by pending patent <font color="blue"><font color="blue">application</font>s</font> or that we were the first to file     patent <font color="blue"><font color="blue">application</font>s</font> for these <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>In addition, to the extent we     license our <font color="blue">intellectual</font> property to other parties, we <font color="blue">may incur expenses as</font>     a result of <font color="blue">contractual <font color="blue">agreements</font></font> in which we indemnify these licensing     <font color="blue">parties against losses incurred</font> if practicing our <font color="blue">intellectual</font> property     <font color="blue">infringes upon</font> the rights of others</td>
    </tr>
    <tr>
      <td>Our <font color="blue">intellectual</font> property and freedom to operate may be challenged by     others, which, if such a challenge were successful, could have a material     adverse effect on our business, results of <font color="blue">operations</font>, <font color="blue">financial condition</font>     and <font color="blue">cash flow</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> and <font color="blue"><font color="blue">proprietary</font> rights</font> of <font color="blue">pharmaceutical</font> and     bio<font color="blue">technology</font> firms, including ours, are <font color="blue"><font color="blue">generally</font> uncertain</font> and involve     <font color="blue">complex legal</font> and factual questions</td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercial success depends</font> in part     on not infringing the patents or <font color="blue"><font color="blue">proprietary</font> rights</font> of others, not breaching     <font color="blue">licenses granted</font> to us and ensuring that we have the <font color="blue"><font color="blue">necessary</font> freedom</font> to     operate  and  <font color="blue">commercialize</font>  our  products</td>
    </tr>
    <tr>
      <td>We are aware of competing     <font color="blue">intellectual</font> property relating to both our GVAX cancer <font color="blue">immunotherapy</font> and     <font color="blue">oncolytic virus therapy</font></td>
    </tr>
    <tr>
      <td>While we believe we have freedom to operate for     both of these programs and are aware of <font color="blue">no issued patents</font> that <font color="blue">could prevent</font>     <font color="blue">us from commercializing</font> the products we are currently developing, <font color="blue">others may</font>     challenge  that  position,  and  from  time  to  time we have received     <font color="blue">communications</font>  <font color="blue">from third parties</font> claiming to have <font color="blue">conflicting rights</font>     relating to <font color="blue">components</font> of our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">periodically</font> review the status of     our products in <font color="blue">development</font> in response to these <font color="blue">communications</font> and more     <font color="blue">generally</font> to ensure that we maintain freedom to operate <font color="blue">with respect</font> all     patents and <font color="blue"><font color="blue">proprietary</font> rights</font> of others</td>
    </tr>
    <tr>
      <td>Nonetheless, if any such claim     were successful, we could be required to obtain licenses to a <font color="blue">third party</font>’s     <font color="blue">technologies</font> or biological or <font color="blue">chemical reagents</font> in order to market our     products</td>
    </tr>
    <tr>
      <td>Moreover, we may choose to <font color="blue">voluntarily seek such</font> a license in     order to avoid the expense and <font color="blue">uncertainty</font> of <font color="blue">fully defending</font> our position</td>
    </tr>
    <tr>
      <td>In <font color="blue">either such event</font>, the failure to license any <font color="blue">technologies</font> or biological     or <font color="blue">chemical reagents</font> required to <font color="blue">commercialize</font> our <font color="blue">technologies</font> or products     <font color="blue">at reasonable cost may</font> have a material adverse effect on our business,     results of <font color="blue">operations</font>, <font color="blue">financial condition</font> and <font color="blue">cash flow</font></td>
    </tr>
    <tr>
      <td>We may have to engage in <font color="blue">litigation</font>, <font color="blue">which could</font> result in substantial cost,     to enforce our patents or to determine the scope and validity of other     parties’ <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>To determine the priority of <font color="blue">inventions</font>, the <font color="blue">United States </font>Patent and     Trademark Office (USPTO) <font color="blue">frequently</font> declares <font color="blue"><font color="blue">interference proceeding</font>s</font></td>
    </tr>
    <tr>
      <td>In     Europe,  patents  can be <font color="blue">revoked through opposition <font color="blue">proceedings</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue"><font color="blue">proceedings</font> could</font> result in an <font color="blue">adverse decision as</font> to the priority of our     <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently involved</font> in an <font color="blue">interference proceeding</font> related to one     of our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We have filed an appeal of the <font color="blue">final decision from</font> the     USPTO relating to an <font color="blue">interference proceeding</font> pending since 1996 with Applied     Research  Systems  Holding  NV  (ARS) <font color="blue">concerning</font> a patent and patent     <font color="blue">application</font> related to gene activation <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>ARS has <font color="blue">also appealed</font> the     decision</td>
    </tr>
    <tr>
      <td>The result of the appeal is <font color="blue">uncertain at</font> this time</td>
    </tr>
    <tr>
      <td>We are not     <font color="blue">currently involved</font> in any other <font color="blue"><font color="blue">interference proceeding</font>s</font></td>
    </tr>
    <tr>
      <td>We were recently     informed that one of our patents for gene activation <font color="blue">technology</font> was denied     in an <font color="blue">appeal proceeding</font> in Europe, which <font color="blue">adversely</font>                                         20       _________________________________________________________________    [73]Table of <font color="blue">Contents       </font>affects our ability to receive <font color="blue">royalties on sales</font> of <font color="blue">products employing</font> this     <font color="blue">technology</font> under certain of our <font color="blue">license <font color="blue">agreements</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the outcome of these <font color="blue">proceedings</font></td>
    </tr>
    <tr>
      <td>An adverse result     in any of these <font color="blue"><font color="blue">proceedings</font> could</font> have an adverse effect on our <font color="blue">intellectual</font>     <font color="blue">property position</font> in these areas and on our business as a whole</td>
    </tr>
    <tr>
      <td>If we lose     in any <font color="blue">such proceeding</font>, our patents or patent <font color="blue"><font color="blue">application</font>s</font> that are the     subject matter of the <font color="blue">proceeding may</font> be invalidated or may not be permitted     to <font color="blue">issue as patents</font></td>
    </tr>
    <tr>
      <td>Consequently, we may be required to obtain a license     from the <font color="blue">prevailing party</font> in order to continue the portion of our business     that relates to the proceeding</td>
    </tr>
    <tr>
      <td>Such <font color="blue">license may</font> not be available to us on     acceptable  terms or on any terms, and we may have to <font color="blue">discontinue</font> that     portion of our business</td>
    </tr>
    <tr>
      <td>We may be involved in other interference and/or     opposition <font color="blue">proceedings</font> in the future</td>
    </tr>
    <tr>
      <td>We believe that there <font color="blue">will continue</font> to     be  <font color="blue">significant</font>  <font color="blue">litigation</font> in the industry regarding patent and other     <font color="blue">intellectual</font> property rights</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue"><font color="blue">competitive</font> position</font> may</font> be <font color="blue">adversely</font> <font color="blue">affected by</font> our limited ability to     protect and control unpatented <font color="blue">trade secrets</font>, know-how and other     <font color="blue">technological innovation</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">competitors</font>  may  <font color="blue">independently</font>  develop similar or better     <font color="blue">proprietary</font> information and <font color="blue">techniques</font> and disclose <font color="blue">them publicly</font></td>
    </tr>
    <tr>
      <td>Also,     <font color="blue">others may</font> gain access to our <font color="blue">trade secrets</font>, and we may not be able to     <font color="blue">meaningfully protect</font> our rights to our unpatented <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>We require our employees and <font color="blue">consultants</font> to execute <font color="blue"><font color="blue">confidential</font>ity</font>     <font color="blue"><font color="blue">agreements</font> upon</font> the <font color="blue">commencement</font> of <font color="blue">employment</font> or consulting <font color="blue">relationships</font>     with  us</td>
    </tr>
    <tr>
      <td>These  <font color="blue"><font color="blue">agreements</font> provide</font> that all <font color="blue">confidential</font> information     developed  by  or made known to an individual during the course of the     <font color="blue">employment</font> or consulting relationship <font color="blue">generally</font> must be kept <font color="blue">confidential</font></td>
    </tr>
    <tr>
      <td>In  the  case of employees, the <font color="blue"><font color="blue">agreements</font> provide</font> that all <font color="blue">inventions</font>     relating to our business conceived by the employee while employed by us are     our  exclusive  property</td>
    </tr>
    <tr>
      <td>These <font color="blue">agreements</font> may not <font color="blue">provide meaningful</font>     protection  for  our <font color="blue">trade secrets</font> in the event of <font color="blue">unauthorized use</font> or     <font color="blue">disclosure</font> of such information</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may develop therapies for the diseases that we are targeting     that are more advanced or more <font color="blue">effective</font> than ours, <font color="blue">which could</font> <font color="blue">adversely</font>     affect our <font color="blue"><font color="blue">competitive</font> position</font>, or they may <font color="blue">commercialize</font> products more     <font color="blue">rapidly than</font> we do, which may <font color="blue">adversely</font> affect our <font color="blue"><font color="blue">competitive</font> position</font></td>
    </tr>
    <tr>
      <td>There are many <font color="blue">companies pursuing programs</font> for the treatment of     cancer</td>
    </tr>
    <tr>
      <td>Some of these <font color="blue">competitors</font> are large bio<font color="blue">technology</font> or <font color="blue">pharmaceutical</font>     companies, such as Amgen, Bristol-Myers Squibb, Genentech, Novartis, Roche     and sanofi-aventis Group, which have greater experience and <font color="blue">resources than</font>     we do in developing products, in undertaking pre<font color="blue">clinical testing</font> and human     <font color="blue"><font color="blue">clinical trial</font>s</font> of new <font color="blue"><font color="blue">pharmaceutical</font> products</font>, in obtaining FDA and other     <font color="blue"><font color="blue">regulatory</font> approval</font>s of products, and in <font color="blue">manufacturing</font> and <font color="blue">marketing new</font>     therapies</td>
    </tr>
    <tr>
      <td>We are <font color="blue">also competing with</font> other bio<font color="blue">technology</font> companies which     have <font color="blue">prostate cancer</font> <font color="blue">immunotherapy</font> products in <font color="blue">various stages</font> of clinical     <font color="blue">development</font> such as Dendreon Corporation, Therion Biologics Corporation and     Onyvax, Ltd</td>
    </tr>
    <tr>
      <td>Some <font color="blue">competitors</font> are pursuing product <font color="blue">development</font> strategies that are     similar to ours, <font color="blue">particularly</font> <font color="blue">with respect</font> to our cancer <font color="blue">immunotherapy</font> and     <font color="blue">oncolytic virus therapy</font> programs</td>
    </tr>
    <tr>
      <td>Certain of these <font color="blue">competitors</font>’ products are     in more advanced stages of product <font color="blue">development</font> and <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">compete with</font> other clinical-stage companies and <font color="blue">institutions</font> for clinical     trial <font color="blue">participants</font>, <font color="blue">which could</font> reduce our ability to <font color="blue">recruit <font color="blue">participants</font></font>     for our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Delay in recruiting <font color="blue">clinical trial</font> <font color="blue">participants</font>     could <font color="blue">adversely</font> affect our ability to bring a product to market prior to our     <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may develop <font color="blue">technologies</font> and products that are     more <font color="blue">effective</font> than ours, or that would render our <font color="blue">technology</font> and products     <font color="blue">less <font color="blue">competitive</font></font> or obsolete</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitive</font> position</font> and those of our <font color="blue">competitors</font> can vary based     on  the  performance  of products in <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, our     <font color="blue">competitors</font>  may  obtain  <font color="blue">patent protection</font> or FDA or other <font color="blue">regulatory</font>     approvals and <font color="blue">commercialize</font> products more <font color="blue">rapidly than</font> we do, which may     <font color="blue">impact future sales</font> of our products</td>
    </tr>
    <tr>
      <td>We also may not have the access that     some of our <font color="blue">competitors</font> have to <font color="blue">biological materials <font color="blue">necessary</font></font> to support     the research, <font color="blue">development</font> or <font color="blue">manufacturing</font> of planned therapies</td>
    </tr>
    <tr>
      <td>If we are     <font color="blue">permitted by</font> the FDA or other <font color="blue">regulatory</font> agencies to <font color="blue">commence commercial</font>     sales of products, we will also be competing <font color="blue">with respect</font> to                                         21       _________________________________________________________________    [74]Table of <font color="blue">Contents       </font><font color="blue">marketing capabilities</font> and <font color="blue">manufacturing</font> efficiency, areas in which we have     limited or no experience</td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">competition among products approved</font>     for sale will be based, among other things, on:         •  <font color="blue">product efficacy</font>;         •  price;         •  safety;         •  re<font color="blue">liability</font>;         •  <font color="blue">availability</font>;         •  <font color="blue">reimbursement</font>;         •  <font color="blue">patent protection</font>; and         •  sales, marketing and <font color="blue"><font color="blue">distribution</font> capabilities</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitive</font> position</font> also depends upon our ability to attract and     retain <font color="blue">qualified personnel</font>, develop <font color="blue">proprietary</font> products or processes, and     <font color="blue">secure sufficient funding</font> for the often-lengthy period between product     <font color="blue">conception</font> and <font color="blue">commercial sales</font></td>
    </tr>
    <tr>
      <td>To the extent we <font color="blue">depend on</font> strategic partners to sell, market or distribute     our products, we will have reduced control over the success of the sales,     marketing and <font color="blue">distribution</font> of our <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>We  have  no  experience in sales, marketing or <font color="blue">distribution</font> of     <font color="blue">bio<font color="blue"><font color="blue">pharmaceutical</font> products</font></font></td>
    </tr>
    <tr>
      <td>We may in the future rely on sales, marketing     and <font color="blue">distribution</font> expertise of <font color="blue">potential corporate partners</font> for our initial     products</td>
    </tr>
    <tr>
      <td>The  decision to market <font color="blue">future products</font> directly or through     <font color="blue">corporate partners will</font> be <font color="blue">based on</font> a number of factors, including:         •  <font color="blue">market size</font> and <font color="blue">concentration</font>;         •  size and expertise of the partner’s sales force in a particular     market; and         •  our <font color="blue">overall strategic <font color="blue">objectives</font></font></td>
    </tr>
    <tr>
      <td>If we choose to <font color="blue">rely on strategic partners</font> for the sale, marketing or     <font color="blue">distribution</font> of our <font color="blue">future products</font>, we will have <font color="blue">less control over</font> the     success of our products and <font color="blue">will depend heavily upon</font> our partners’ abilities     and <font color="blue">dedication</font> to our products</td>
    </tr>
    <tr>
      <td>We cannot assure you that these future     <font color="blue">strategic partnerships will</font> be <font color="blue">available on</font> favorable terms, if at all, nor     can we assure you that they will enhance our business</td>
    </tr>
    <tr>
      <td>We may in the future be exposed to product <font color="blue">liability</font> claims, <font color="blue">which could</font>     <font color="blue">adversely</font> affect our business, results of <font color="blue">operations</font>, <font color="blue">financial condition</font>     and <font color="blue">cash flow</font></td>
    </tr>
    <tr>
      <td>Clinical trials or marketing of any of our <font color="blue">potential products</font> may     expose us to <font color="blue">liability</font> claims resulting from the use of our products</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>claims might be made by <font color="blue">clinical trial</font> <font color="blue">participants</font> and <font color="blue">associated parties</font>,     consumers, health care providers or sellers of our products</td>
    </tr>
    <tr>
      <td>We currently     maintain product <font color="blue">liability</font> insurance <font color="blue">with respect</font> to each of our clinical     trials</td>
    </tr>
    <tr>
      <td>We may not be able to maintain insurance or obtain sufficient     <font color="blue">coverage at</font> a reasonable cost, given the <font color="blue">increasing cost</font> of insurance in     today’s  insurance  market</td>
    </tr>
    <tr>
      <td>An  <font color="blue">inability</font> to maintain <font color="blue">insurance at</font> an     acceptable cost, or at all, could result in a breach of terms of our product     <font color="blue">license <font color="blue">agreements</font></font> or <font color="blue">could prevent</font> or inhibit the <font color="blue">clinical testing</font> or     <font color="blue">commercialization</font>  of  our  products or <font color="blue">otherwise affect</font> our financial     condition</td>
    </tr>
    <tr>
      <td>A claim, <font color="blue">particularly</font> resulting from a <font color="blue">clinical trial</font>, on any of     our <font color="blue">insurance policies</font> or a <font color="blue">product recall could</font> have a material adverse     effect on our business, results of <font color="blue">operations</font>, <font color="blue">financial condition</font> and cash     flow</td>
    </tr>
    <tr>
      <td>Our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font> could suffer as     a result of <font color="blue">future <font color="blue">strategic <font color="blue">acquisition</font></font>s</font> and <font color="blue">investment</font>s</td>
    </tr>
    <tr>
      <td>We may engage in <font color="blue">future <font color="blue">acquisition</font>s</font> or <font color="blue">investment</font>s that <font color="blue">could dilute</font>     our <font color="blue">existing <font color="blue">stockholders</font></font> or cause us to <font color="blue">incur contingent liabilities</font>,     <font color="blue">commitments</font>, debt or <font color="blue">significant</font> expense</td>
    </tr>
    <tr>
      <td>From time to time, in the ordinary                                         22       _________________________________________________________________    [75]Table of <font color="blue">Contents       </font>course of business, we <font color="blue">may evaluate potential <font color="blue">acquisition</font>s</font> or <font color="blue">investment</font>s in     related <font color="blue">businesses</font>, products or <font color="blue">technologies</font>, although we currently have no     <font color="blue">commitments</font> or <font color="blue">agreements</font> for any <font color="blue">such <font color="blue">acquisition</font>s</font> or <font color="blue">investment</font>s</td>
    </tr>
    <tr>
      <td>We may     not be <font color="blue">successful with</font> any <font color="blue">strategic <font color="blue">acquisition</font></font> or <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>Any future     <font color="blue">acquisition</font> or <font color="blue">investment</font> could harm our business, <font color="blue">financial condition</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we engage in <font color="blue">future <font color="blue">acquisition</font>s</font>, we may not be able to fully     integrate  the  acquired  companies and their <font color="blue">intellectual</font> property or     personnel</td>
    </tr>
    <tr>
      <td>Our  attempts to do so may place <font color="blue">additional</font> burdens on our     <font color="blue">management</font> and <font color="blue">infrastructure</font></td>
    </tr>
    <tr>
      <td>Future <font color="blue">acquisition</font>s will also subject us to a     number of risks, including:         •  the loss of <font color="blue">key personnel</font> and business <font color="blue">relationships</font>;         •  <font color="blue"><font color="blue">difficult</font>ies associated with assimilating</font> and <font color="blue">integrating</font> the new     personnel and <font color="blue">operations</font> of the acquired companies;         •  the <font color="blue">potential disruption</font> of our ongoing business;         •  the <font color="blue">expense associated with maintenance</font> of diverse standards, controls,     procedures, employees and clients;         •  the diversion of <font color="blue">resources from</font> the <font color="blue">development</font> of our own <font color="blue">proprietary</font>     <font color="blue">technology</font>; and         •  our <font color="blue">inability</font> to <font color="blue">generate revenue from</font> acquired <font color="blue">technology</font> sufficient     to meet our <font color="blue">objectives</font> in undertaking the <font color="blue">acquisition</font> or even to offset the     associated <font color="blue">acquisition</font> and <font color="blue">maintenance costs</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> are vulnerable to interruption by fire, earthquake, power     loss, tele<font color="blue">communications</font> failure, terrorist activity and other <font color="blue">events beyond</font>     our control, <font color="blue">which could</font> result in a material adverse effect on our     business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">facilities</font> in <font color="blue">California </font>have, in the past, been subject to     <font color="blue">electrical blackouts as</font> a result of a shortage of <font color="blue">available electrical</font>     power</td>
    </tr>
    <tr>
      <td>Future <font color="blue">blackouts could disrupt</font> the <font color="blue">operations</font> of our <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>In     addition, we do not carry sufficient business <font color="blue">interruption insurance</font> to     <font color="blue">compensate us</font> for <font color="blue">actual losses from interruption</font> of our business that may     occur,  and any losses or <font color="blue">damages incurred by us could</font> have a material     adverse effect on our business</td>
    </tr>
    <tr>
      <td>We are vulnerable to a <font color="blue">major earthquake</font> and     other <font color="blue">calamities</font></td>
    </tr>
    <tr>
      <td>Most of our <font color="blue">facilities</font> are located in <font color="blue">seismically</font> active     regions</td>
    </tr>
    <tr>
      <td>We have not undertaken a <font color="blue">systematic analysis</font> of the potential     <font color="blue">consequences</font> to our business and financial results from a <font color="blue">major earthquake</font>     and do not have a recovery plan for fire, earthquake, power loss, terrorist     activity or similar <font color="blue">disasters</font></td>
    </tr>
    <tr>
      <td>We are unable to predict the effects of any     such event, but the <font color="blue">effects could</font> be <font color="blue">seriously harmful</font> to our business</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> our key technical and <font color="blue">management</font> personnel to advance our     <font color="blue">technology</font>, and the loss of these personnel <font color="blue">could impair</font> the <font color="blue">development</font> of     our products</td>
    </tr>
    <tr>
      <td>We rely and <font color="blue">will continue</font> to rely on our key <font color="blue">management</font> and scientific     staff, all of whom are employed at-will</td>
    </tr>
    <tr>
      <td>The loss of <font color="blue">key personnel</font> or the     failure to recruit <font color="blue">necessary</font> <font color="blue">additional</font> <font color="blue">qualified personnel</font> could have a     material adverse effect on our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>There is     <font color="blue">intense competition from</font> other companies, research and academic <font color="blue">institutions</font>     and other <font color="blue">organizations</font> for <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>We may not be able to     continue to attract and retain the <font color="blue">qualified personnel</font> <font color="blue">necessary</font> for the     <font color="blue">development</font> of our business</td>
    </tr>
    <tr>
      <td>We will need to continue to <font color="blue">recruit experts</font> in     the  areas  of <font color="blue">clinical testing</font>, <font color="blue">manufacturing</font>, finance, marketing and     <font color="blue">distribution</font> and to develop <font color="blue">additional</font> expertise in our <font color="blue">existing personnel</font></td>
    </tr>
    <tr>
      <td>If we do not succeed in <font color="blue">recruiting <font color="blue">necessary</font> personnel</font> or developing this     expertise, our business could suffer <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>Various materials that we use are <font color="blue">purchased from single qualified suppliers</font>,     <font color="blue">which could</font> result in our <font color="blue">inability</font> to <font color="blue">secure sufficient materials</font> to     conduct our business</td>
    </tr>
    <tr>
      <td>Most of the <font color="blue">materials which</font> we purchase for use in our <font color="blue">manufacturing</font>     <font color="blue">operations</font> are subject to a <font color="blue">supplier qualification program</font></td>
    </tr>
    <tr>
      <td>In the event     that we or the supplier deems the proffered material or the <font color="blue">supplier no</font>     <font color="blue">longer appropriate</font> to support our cGMP <font color="blue">operations</font>, we may face <font color="blue">significant</font>     <font color="blue">additional</font>  expenses  to  find  and qualify alternate materials and/or     suppliers</td>
    </tr>
    <tr>
      <td><font color="blue">Depending </font>on the magnitude of the <font color="blue">potential difference between</font>     materials and/or suppliers currently used and alternate materials and/or     <font color="blue">suppliers which may</font> be identified,                                         23       _________________________________________________________________    [76]Table of <font color="blue">Contents       </font>there is no guarantee that FDA or other health <font color="blue">authorities</font> will deem the     alternative materials and/or suppliers to be comparable, which may require     us to perform <font color="blue">additional</font> and/or extended clinical studies and <font color="blue">could delay</font>     <font color="blue">product approval</font></td>
    </tr>
    <tr>
      <td>Some of the <font color="blue">materials which</font> we purchase for use in our <font color="blue">manufacturing</font>     <font color="blue">operations</font> are sole-sourced, meaning only one known supplier exists</td>
    </tr>
    <tr>
      <td>In the     event of a <font color="blue">significant</font> interruption of sole-sourced supplies, the quantity     of our <font color="blue">inventory may</font> not be adequate to complete our <font color="blue"><font color="blue">clinical trial</font>s</font> or to     launch our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Inventions </font>or <font color="blue">processes discovered by</font> our <font color="blue">outside scientific</font> <font color="blue">collaborators</font>     may not become our property, which may affect our <font color="blue"><font color="blue">competitive</font> position</font></td>
    </tr>
    <tr>
      <td>We  rely  on  the  continued <font color="blue">availability</font> of <font color="blue">outside scientific</font>     <font color="blue">collaborators</font> performing research</td>
    </tr>
    <tr>
      <td>These <font color="blue">relationships</font> <font color="blue">generally</font> may be     <font color="blue">terminated at</font> any time by the collaborator, typically by giving 30 days     notice</td>
    </tr>
    <tr>
      <td>These scientific <font color="blue">collaborators</font> are not our employees</td>
    </tr>
    <tr>
      <td>As a result,     we have limited control over their <font color="blue">activities</font> and can expect that only     limited amounts of their time will be dedicated to our <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">arrangements</font> with these <font color="blue">collaborators</font>, as well as those with our scientific     <font color="blue">consultants</font>, provide that any rights we obtain as a result of their research     <font color="blue">efforts will</font> be subject to the rights of the research <font color="blue">institutions</font> for which     they work</td>
    </tr>
    <tr>
      <td>In addition, some of these <font color="blue">collaborators</font> have consulting or other     advisory <font color="blue">arrangements</font> with other entities that <font color="blue">may conflict with</font> their     <font color="blue">obligations</font> to us</td>
    </tr>
    <tr>
      <td>For these reasons, <font color="blue">inventions</font> or <font color="blue">processes discovered by</font>     our scientific <font color="blue">collaborators</font> or <font color="blue">consultants</font> may not become our property</td>
    </tr>
    <tr>
      <td>The prices of our <font color="blue">common stock</font> and <font color="blue">convertible senior</font> notes are likely to     continue to be volatile in the future</td>
    </tr>
    <tr>
      <td>The <font color="blue">stock prices</font> of bio<font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies,     including ours, have <font color="blue">historically been highly volatile</font></td>
    </tr>
    <tr>
      <td><font color="blue">Since January </font>1,     2003, our stock price has <font color="blue">fluctuated between</font> a high closing price of dlra15dtta93     on March 4, 2004 and a low closing price of dlra4dtta48 on October 12, 2005</td>
    </tr>
    <tr>
      <td>The     market  has from time to time experienced <font color="blue">significant</font> price and volume     <font color="blue">fluctuations</font> that are unrelated to the operating performance of particular     companies</td>
    </tr>
    <tr>
      <td>In addition, as our <font color="blue">convertible senior</font> notes are <font color="blue">convertible into</font>     shares of our <font color="blue">common stock</font>, volatility or <font color="blue">depressed prices</font> of our common     <font color="blue">stock could</font> have a similar effect on the <font color="blue">trading price</font> of the notes</td>
    </tr>
    <tr>
      <td>Also,     interest rate <font color="blue">fluctuations</font> can affect the price of our <font color="blue">convertible senior</font>     notes</td>
    </tr>
    <tr>
      <td>The following factors, among others, may affect the prices of our     <font color="blue">common stock</font> and notes:         •  <font color="blue"><font color="blue">announcement</font>s</font> of data from, or material <font color="blue">development</font>s in, our clinical     trials or those of our <font color="blue">competitors</font>, including delays in the <font color="blue">commencement</font>,     progress or <font color="blue">completion</font> of a <font color="blue">clinical trial</font>;         •  <font color="blue">fluctuations</font> in our financial results;         •  the potential of an unfavorable future <font color="blue">resolution with</font> the IRS with     respect to their audit of our fiscal 2000 federal tax return, or to other     potential <font color="blue">tax assessments</font>;         •  <font color="blue"><font color="blue">announcement</font>s</font> of <font color="blue">technological innovation</font>s or <font color="blue">new therapeutic products</font>     by  us  or  our  <font color="blue">competitors</font>, including <font color="blue">innovations</font> or <font color="blue">products by</font> our     <font color="blue">competitors</font>  that may require us to redesign, and <font color="blue">therefore delay</font>, our     <font color="blue"><font color="blue">clinical trial</font>s</font> to account for those <font color="blue">innovations</font> or products;         •  <font color="blue"><font color="blue">announcement</font>s</font> of changes in <font color="blue"><font color="blue"><font color="blue">government</font>al</font> regulation affecting us</font> or our     <font color="blue">competitors</font>;         •  <font color="blue"><font color="blue">announcement</font>s</font> of <font color="blue"><font color="blue">regulatory</font> approval</font> or <font color="blue">disapproval</font> of our or our     <font color="blue">competitors</font>’ products;          •   <font color="blue"><font color="blue">announcement</font>s</font>  of  new collaborative <font color="blue">relationships</font> by us or our     <font color="blue">competitors</font>;         •  <font color="blue">development</font>s in patent or other <font color="blue"><font color="blue">proprietary</font> rights</font> affecting us or our     <font color="blue">competitors</font>;         •  public concern as to the safety of products developed by us or other     bio<font color="blue">technology</font> and <font color="blue">pharmaceutical</font> companies;         •  general market <font color="blue">conditions</font>;         •  material <font color="blue">development</font>s related to our <font color="blue">minority interest</font> in Ceregene,     Inc</td>
    </tr>
    <tr>
      <td>;                                         24       _________________________________________________________________    [77]Table of <font color="blue">Contents       </font>  •  <font color="blue">fluctuations</font> in price and volume in the stock market in general, or in     the trading of the stock of bio<font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies in     particular, that are unrelated to our operating performance;          •   issuances  of securities in equity, debt or other <font color="blue">financings</font> or     issuances of <font color="blue">common stock</font> upon <font color="blue">conversion</font> of our <font color="blue">convertible senior</font> notes;         •  unforeseen <font color="blue">litigation</font>;         •  sales of <font color="blue">common stock</font> by <font color="blue">existing <font color="blue">stockholders</font></font>; and         •  the <font color="blue">perception</font> that <font color="blue">such issuances</font> or <font color="blue">sales could</font> occur</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">stockholders</font> may</font> be <font color="blue">diluted by</font> the <font color="blue">conversion</font> of <font color="blue">outstanding convertible</font>     senior notes</td>
    </tr>
    <tr>
      <td>In  October and November 2004 we issued and sold dlra145dtta0 million     <font color="blue">aggregate principal amount</font> of notes which are <font color="blue">convertible into</font> our common     stock, initially at the <font color="blue">conversion</font> price of dlra9dtta10 per share, equal to a     <font color="blue">conversion</font> rate of <font color="blue">approximately</font> 109dtta8901 shares per dlra1cmam000 principal amount     of notes, subject to <font color="blue">adjustment</font></td>
    </tr>
    <tr>
      <td>The holders of the notes <font color="blue">may choose at</font> any     time to convert their notes into <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The number of shares of     common  stock issuable upon <font color="blue">conversion</font> of the notes, and therefore the     dilution of existing <font color="blue">common stock</font>holders, <font color="blue">could increase as</font> a result of an     <font color="blue">event triggering</font> the <font color="blue">antidilution rights</font> of the notes, including certain     <font color="blue">acquisition</font>s of the Company in which 10prca or more of the <font color="blue">consideration paid</font>     for our <font color="blue">common stock</font> in the <font color="blue">transaction</font> is in the form of cash or securities     that are not <font color="blue">freely tradable</font></td>
    </tr>
    <tr>
      <td><font color="blue">Conversion </font>of our <font color="blue">convertible senior</font> notes     would result in issuance of <font color="blue">additional</font> shares of <font color="blue">common stock</font>, diluting     existing <font color="blue">common stock</font>holders</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">stockholders</font> may</font> be diluted, or our <font color="blue">common stock</font> price may be <font color="blue">adversely</font>     affected, by the exercise of <font color="blue"><font color="blue">outstanding stock</font> options</font> or other issuances of     our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We may issue <font color="blue">additional</font> <font color="blue">common stock</font>, preferred stock, or securities     convertible  into  or  exchangeable for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Furthermore,     <font color="blue">substantially</font> all shares of <font color="blue">common stock</font> for which our <font color="blue">outstanding stock</font>     options are exercisable are, once they have been purchased, eligible for     <font color="blue">immediate sale</font> in the <font color="blue">public market</font></td>
    </tr>
    <tr>
      <td>The issuance of <font color="blue">common stock</font>, preferred     stock or securities <font color="blue">convertible into</font> or exchangeable for our <font color="blue">common stock</font> or     the exercise of <font color="blue">stock options would dilute existing investors</font> and could     <font color="blue">adversely</font> affect the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We have adopted anti-takeover defenses that could make it <font color="blue">difficult</font> for     another company to acquire control of us or <font color="blue">could limit</font> the <font color="blue">price investors</font>     might be willing to pay for our stock</td>
    </tr>
    <tr>
      <td>Certain provisions of our <font color="blue">certificate</font> of incorporation, bylaws, debt     <font color="blue">instruments</font> and <font color="blue">Delaware </font>law could make it more <font color="blue">difficult</font> for a <font color="blue">third party</font>     to  acquire us, even if doing so <font color="blue">would benefit</font> our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>provisions include the adoption of a Stockholder Rights Plan, <font color="blue">commonly known</font>     as a “<font color="blue">poison pill</font></td>
    </tr>
    <tr>
      <td>” Under the Stockholder Rights Plan, we made a dividend     <font color="blue">distribution</font> of <font color="blue">one preferred</font> share purchase right for each share of our     <font color="blue">common stock</font> outstanding as of August 21, 1995 and each share of our common     stock  issued after that date</td>
    </tr>
    <tr>
      <td>In July 2000, we made <font color="blue">certain technical</font>     changes to amend the plan and extended the term of such plan until 2010</td>
    </tr>
    <tr>
      <td>The     rights are <font color="blue">exercisable only</font> if an acquirer purchases 15 percent or more of     our <font color="blue">common stock</font> or announces a <font color="blue">tender offer</font> for 15 percent or more of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Upon exercise, holders other than the <font color="blue">acquirer may purchase</font>     our stock at a discount</td>
    </tr>
    <tr>
      <td><font color="blue">Our Board of Directors </font><font color="blue">may terminate</font> the rights     plan at any time or <font color="blue">under certain circumstances redeem</font> the rights</td>
    </tr>
    <tr>
      <td><font color="blue">Because     </font>the rights may <font color="blue">substantially</font> dilute the stock ownership of a person or group     attempting to take <font color="blue">us over without</font> the approval of our Board of Directors,     the plan could make it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire us (or a     <font color="blue">significant</font> percentage of our outstanding capital stock) without first     <font color="blue">negotiating with</font> our Board of Directors regarding such <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>provisions and <font color="blue">certain provisions</font> of the <font color="blue">Delaware </font>General Corporation Law     may have the effect of <font color="blue">deterring hostile takeovers</font> or <font color="blue">otherwise delaying</font> or     preventing changes in our <font color="blue">management</font> or in the control of our company,     including <font color="blue">transaction</font>s in which our <font color="blue">stockholders</font> might otherwise receive a     <font color="blue">premium over</font> the <font color="blue">fair market value</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>25       _________________________________________________________________    [78]Table of <font color="blue">Contents       </font>Due to the <font color="blue">potential value</font> of our strategic <font color="blue">investment</font>s, we could be     determined to be an <font color="blue">investment</font> company, and if such a de<font color="blue">termination</font> were     made, we would become subject to <font color="blue">significant</font> regulation that would <font color="blue">adversely</font>     affect our business</td>
    </tr>
    <tr>
      <td>Our non-controlling position in Ceregene, along with <font color="blue">investment</font>s of     our <font color="blue">available cash resources</font> in <font color="blue">certain types</font> of fixed-income securities,     could be considered “<font color="blue">investment</font> securities” under <font color="blue">the Investment Company Act</font>     of 1940, raising a question of whether we are an <font color="blue">investment</font> company required     to register and be regulated under <font color="blue">the Investment Company Act</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulation     </font>under <font color="blue">the Investment Company Act</font>, or a de<font color="blue">termination</font> that we failed to     register when required to do so, <font color="blue">could materially</font> and <font color="blue">adversely</font> affect our     business</td>
    </tr>
    <tr>
      <td>We  believe  that we are primarily engaged in the research,     <font color="blue">development</font> and <font color="blue">commercialization</font> of <font color="blue">biological cancer therapies</font> and that     any  <font color="blue">investment</font>  securities  are  <font color="blue">ancillary</font>  to  our primary business</td>
    </tr>
    <tr>
      <td>Nevertheless, possible required <font color="blue">dispositions</font> of non-controlling <font color="blue">investment</font>s     could <font color="blue">adversely</font> affect our future reported results</td>
    </tr>
    <tr>
      <td>If we fail to maintain an <font color="blue">effective</font> system of <font color="blue">internal controls</font>, we may not     be able to <font color="blue">accurately</font> report our financial results, maintain investor     confidence or <font color="blue">prevent fraud</font></td>
    </tr>
    <tr>
      <td><font color="blue">Effective </font><font color="blue">internal controls</font> are <font color="blue">necessary</font> for us to <font color="blue">provide reliable</font>     financial reports, maintain <font color="blue">investor confidence</font> and <font color="blue">prevent fraud</font></td>
    </tr>
    <tr>
      <td>As our     <font color="blue">operations</font> have grown, as well as part of our <font color="blue">examination</font> of our internal     systems in response to Sarbanes-Oxley <font color="blue"><font color="blue">requirement</font>s</font>, we have discovered in     the past, and may in the future discover, areas of our <font color="blue">internal controls</font>     that could be improved</td>
    </tr>
    <tr>
      <td>None of these issues have risen to the level that we     were unable to attest to the <font color="blue">effective</font>ness of our <font color="blue">internal controls</font> when we     were required to do so</td>
    </tr>
    <tr>
      <td>During fiscal 2005, we took a number of steps to     improve our <font color="blue">internal controls</font></td>
    </tr>
    <tr>
      <td>Although we believe that all of these efforts     have strengthened our <font color="blue">internal controls</font>, we continue to work to improve our     <font color="blue">internal controls</font></td>
    </tr>
    <tr>
      <td>We cannot be certain that these <font color="blue">measures will ensure</font> that     we implement and maintain <font color="blue">adequate controls over</font> our <font color="blue">financial processes</font> and     reporting in the future</td>
    </tr>
    <tr>
      <td>Any failure to implement required new or improved     controls, or <font color="blue">difficult</font>ies encountered in their implementation, could harm     our operating results or cause us to fail to meet our reporting <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>Inferior <font color="blue">internal controls</font> could also cause investors to <font color="blue">lose confidence</font> in     our reported financial information, <font color="blue">which could</font> have a negative effect on     the <font color="blue">trading price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Recent <font color="blue">accounting pronouncements will impact</font> our future results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2004, the Financial Accounting Standards Board, or FASB,     issued a revision of Financial Accounting Standards Nodtta 123, or SFAS 123R,     which  requires  all  share-based payments to employees and <font color="blue">directors</font>,     including grants of <font color="blue">employee stock options</font>, to be recognized in the income     statement  based  on their values</td>
    </tr>
    <tr>
      <td>We expect to calculate the value of     share-based payments under SFAS 123R on a basis <font color="blue">substantially</font> <font color="blue">consistent</font>     with the <font color="blue">fair value approach</font> of SFAS 123</td>
    </tr>
    <tr>
      <td>We will adopt SFAS 123R in our     <font color="blue"><font color="blue">fiscal quarter</font> beginning</font> January 1, 2006, using the <font color="blue">modified prospective</font>     method</td>
    </tr>
    <tr>
      <td>We expect the adoption of SFAS 123R will have a material <font color="blue">impact on</font>     our results of <font color="blue">operations</font> in that <font color="blue">fiscal quarter</font> and in <font color="blue">each subsequent</font>     quarter, although it will have no <font color="blue">impact on</font> our <font color="blue">overall liquidity</font></td>
    </tr>
    <tr>
      <td>We cannot     <font color="blue">reasonably</font> estimate the impact of adoption because it will <font color="blue">depend on</font> levels     of share-based payments granted in the <font color="blue">future as well as certain assumptions</font>     that can <font color="blue">materially affect</font> the <font color="blue">calculation</font> of the value share-based payments     to employees and <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>However, had we adopted SFAS 123R in prior     periods, the impact of the standard would have <font color="blue">approximated</font> the impact of     SFAS 123 as described in the <font color="blue">disclosure</font> of pro forma net loss and pro forma     loss  per  common  share  in Note 1 of Notes to Consolidated Financial     Statements included under Item 8 of this <font color="blue">Annual Report </font>on Form 10-K The     adoption of SFAS 123R may affect the way we compensate our employees or may     cause other changes in the way we conduct our business</td>
    </tr>
    <tr>
      <td>26       _________________________________________________________________    [79]Table of <font color="blue">Contents       </font>Risks Related to Our Industry       In order for our products to be offered to the public, they <font color="blue">must undergo</font>     extensive <font color="blue">clinical testing</font> and receive <font color="blue">approval from</font> the FDA and other     <font color="blue">regulatory</font> agencies, <font color="blue">which could</font> delay or prevent the <font color="blue">commercialization</font> of     our products</td>
    </tr>
    <tr>
      <td>Human therapeutic products <font color="blue">must undergo</font> rigorous preclinical and     <font color="blue">clinical testing</font> and other <font color="blue">premarket approval procedures by</font> the FDA and     similar  <font color="blue">authorities</font>  in  foreign countries</td>
    </tr>
    <tr>
      <td><font color="blue">Preclinical </font>tests include     <font color="blue">laboratory evaluation</font> of <font color="blue">potential products</font> and <font color="blue">animal studies</font> to assess the     potential  safety  and  efficacy  of the product and its <font color="blue">formulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Initiation </font>of <font color="blue"><font color="blue">clinical trial</font>s</font> requires approval by health <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">trials involve</font> the <font color="blue">administration</font> of the <font color="blue">investigational new drug</font>     to <font color="blue">healthy volunteers</font> or to <font color="blue">patients under</font> the <font color="blue">supervision</font> of a qualified     <font color="blue">principal investigator</font></td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">trials must</font> be conducted in <font color="blue">accordance with</font>     FDA  and  ICH  Good Clinical Practices and the European Clinical Trial     Directive <font color="blue">under protocols</font> that detail the <font color="blue">objectives</font> of the study, the     <font color="blue">parameters</font> to be used to <font color="blue">monitor safety</font> and the <font color="blue">efficacy criteria</font> to be     evaluated</td>
    </tr>
    <tr>
      <td>Other national, foreign and local <font color="blue">regulations</font> may also apply</td>
    </tr>
    <tr>
      <td>The     developer  of  the  drug  must  provide  information  relating  to the     <font color="blue">characterization</font> and controls of the product before <font color="blue">administration</font> to the     <font color="blue">patients participating</font> in the <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>This requires developing     <font color="blue">approved assays</font> of the product to test before <font color="blue">administration</font> to the patient     and  during  the  conduct  of  the  trial</td>
    </tr>
    <tr>
      <td>In addition, developers of     <font color="blue"><font color="blue">pharmaceutical</font> products</font> must provide periodic data regarding <font color="blue"><font color="blue">clinical trial</font>s</font>     to the FDA and other health <font color="blue">authorities</font>, and these health <font color="blue">authorities</font> or our     <font color="blue">Independent Data Monitoring Committees </font>may issue a clinical hold upon a     trial if they do not believe, or cannot confirm, that the trial can be     <font color="blue">conducted without unreasonable risk</font> to the trial <font color="blue">participants</font></td>
    </tr>
    <tr>
      <td>We cannot     assure  you  that US and foreign health <font color="blue">authorities</font> will not issue a     clinical hold <font color="blue">with respect</font> to any of our <font color="blue"><font color="blue">clinical trial</font>s</font> in the future</td>
    </tr>
    <tr>
      <td>The     results of the pre<font color="blue">clinical testing</font> and <font color="blue">clinical testing</font>, together with     chemistry, <font color="blue">manufacturing</font> and controls information, are submitted to the FDA     and other health <font color="blue">authorities</font> in the form of a new drug <font color="blue">application</font> for a     <font color="blue">pharmaceutical</font> product, and in the form of a <font color="blue">biologics license</font> <font color="blue">application</font>     for a biological product, requesting approval to <font color="blue">commence commercial</font> sales</td>
    </tr>
    <tr>
      <td>In  responding to a new drug <font color="blue">application</font> or a <font color="blue">biologics license</font>     <font color="blue">application</font>, the FDA or foreign health <font color="blue">authorities</font> may grant marketing     approvals, request <font color="blue">additional</font> information or further research, or deny the     <font color="blue">application</font> if it determines that the <font color="blue">application</font> does not satisfy its     <font color="blue"><font color="blue">regulatory</font> approval</font> criteria</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font>approval of a new drug <font color="blue">application</font>,     <font color="blue">biologics license</font> <font color="blue">application</font>, or supplement is <font color="blue">never guaranteed</font>, and the     <font color="blue">approval process</font> can take <font color="blue">several years</font> and is <font color="blue">extremely expensive</font></td>
    </tr>
    <tr>
      <td><font color="blue">The FDA     </font>and foreign health <font color="blue">authorities</font> have substantial <font color="blue">discretion</font> in the drug and     biologics <font color="blue">approval process</font>es</td>
    </tr>
    <tr>
      <td>Despite the time and expense incurred, failure     can occur at any stage, and we could encounter problems that cause us to     abandon <font color="blue"><font color="blue">clinical trial</font>s</font> or to repeat or perform <font color="blue">additional</font> preclinical,     clinical or <font color="blue">manufacturing</font>-related studies</td>
    </tr>
    <tr>
      <td><font color="blue">Approvals </font>may not be <font color="blue">granted on</font> a     <font color="blue">timely basis</font>, if at all, and if <font color="blue">granted may</font> not cover all the clinical     <font color="blue">indication</font>s for which we <font color="blue">may seek approval</font></td>
    </tr>
    <tr>
      <td>Also, an approval might contain     <font color="blue">significant</font>  <font color="blue">limitations</font>  in  the  form  of  warnings,  <font color="blue">precautions</font> or     contra<font color="blue">indication</font>s <font color="blue">with respect</font> to <font color="blue">conditions</font> of use</td>
    </tr>
    <tr>
      <td>Even if our products are approved by <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font>, if we fail to     <font color="blue">comply with</font> ongoing <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font>, or if we experience     <font color="blue"><font color="blue">unanticipated</font> problems with</font> our products, these <font color="blue">products could</font> be subject to     <font color="blue">restrictions</font> or <font color="blue">withdrawal from</font> the market</td>
    </tr>
    <tr>
      <td>Any product for which we obtain marketing approval, along with the     <font color="blue">manufacturing</font> processes, post-approval pre-clinical, <font color="blue">manufacturing</font>, clinical     and <font color="blue">safety data</font> and promotional <font color="blue">activities</font> for such product, will be subject     to <font color="blue">continual review</font> and <font color="blue">periodic inspections by</font> the FDA and other <font color="blue">regulatory</font>     bodies</td>
    </tr>
    <tr>
      <td>Even if <font color="blue"><font color="blue">regulatory</font> approval</font> of a product is granted, the approval     may be subject to <font color="blue">limitations</font> on the <font color="blue">indicated uses</font> for which the product     may be marketed or contain <font color="blue"><font color="blue">requirement</font>s</font> for costly post-marketing testing     and surveillance to monitor the safety or efficacy of the product</td>
    </tr>
    <tr>
      <td><font color="blue">Later     </font><font color="blue">discovery</font>  of  <font color="blue">previously unknown problems with</font> our products including     <font color="blue">unanticipated</font>  adverse  events of <font color="blue">unanticipated</font> severity or frequency,     <font color="blue">manufacture</font>r  or  <font color="blue">manufacturing</font>  processes,  or failure to <font color="blue">comply with</font>     <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font>, may result in <font color="blue">restrictions</font> on such products or     <font color="blue">manufacturing</font>  processes,  withdrawal of the <font color="blue">products from</font> the market,     voluntary or mandatory recall, fines, suspension of <font color="blue"><font color="blue">regulatory</font> approval</font>s,     <font color="blue">product seizures</font> or detention, <font color="blue">injunctions</font> or the imposition of civil or     <font color="blue">criminal penalties</font></td>
    </tr>
    <tr>
      <td>27       _________________________________________________________________    [80]Table of <font color="blue">Contents       </font>We are subject to federal, state, local and <font color="blue">foreign laws</font> and <font color="blue">regulations</font>,     and <font color="blue">complying with</font> these may cause us to incur <font color="blue">significant</font> costs</td>
    </tr>
    <tr>
      <td>We are subject to laws and <font color="blue">regulations</font> enforced by the FDA, the DEA,     the <font color="blue">California </font>Department of Health Services, foreign health <font color="blue">authorities</font> and     other <font color="blue">regulatory</font> statutes including:         •  the Occupational Safety and Health Act;         •  the Environmental Protection Act;         •  the Toxic Substances Control Act;         •  the Food, Drug and Cosmetic Act;         •  the Resource Conservation and Recovery Act; and         •  other current and potential federal, state, local or <font color="blue">foreign laws</font> and     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>In particular <font color="blue">with respect</font> to environmental laws, product <font color="blue">development</font>     <font color="blue">activities</font>  involve  the  use of <font color="blue">hazardous materials</font>, and we may incur     <font color="blue">significant</font> costs as a result of the need to <font color="blue">comply with</font> these laws</td>
    </tr>
    <tr>
      <td>Our     research, <font color="blue">development</font> and <font color="blue"><font color="blue">manufacturing</font> <font color="blue">activities</font></font> involve the controlled     use of <font color="blue">hazardous materials</font>, chemicals, viruses and <font color="blue">radioactive compounds</font></td>
    </tr>
    <tr>
      <td>We     are  subject to federal, foreign, state and <font color="blue">local laws</font> and <font color="blue">regulations</font>     governing the use, <font color="blue">manufacture</font>, storage, handling and disposal of these     materials and <font color="blue">waste products</font></td>
    </tr>
    <tr>
      <td>Although we believe that our <font color="blue">safety procedures</font>     for handling and disposing of these materials <font color="blue">comply with</font> the standards     prescribed  by  applicable  laws and <font color="blue">regulations</font>, we <font color="blue">cannot completely</font>     eliminate the risk of <font color="blue">contamination</font> or injury, by <font color="blue">accident</font> or as the result     of <font color="blue">intentional</font> acts of terrorism, from these materials</td>
    </tr>
    <tr>
      <td>In the event of an     <font color="blue">accident</font>, we could be held liable for any damages that result, and any     resulting <font color="blue">liability</font> could exceed our resources</td>
    </tr>
    <tr>
      <td>We do not carry insurance     for potential exposures <font color="blue">which could</font> result from these risks</td>
    </tr>
    <tr>
      <td>We may also be     required to incur <font color="blue">significant</font> costs to <font color="blue">comply with</font> environmental laws and     <font color="blue">regulations</font> in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font>from third-party payers may become more restricted in the     future, which may reduce demand for our products</td>
    </tr>
    <tr>
      <td>There is <font color="blue">uncertainty</font> related to the extent to which third-party payers     will  cover  and pay for <font color="blue">newly approved therapies</font></td>
    </tr>
    <tr>
      <td>Sales of our future     <font color="blue">products will</font> be influenced by the <font color="blue">willingness</font> of third-party payers to     provide <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">both domestic</font> and foreign markets, sales of our     <font color="blue">potential products</font> will depend in part upon coverage and <font color="blue">payment amounts</font>     from third-party payers, including:         •  <font color="blue"><font color="blue">government</font> agencies</font>;         •  <font color="blue">private health care insurers</font> and other <font color="blue">health care payers such as</font>     health maintenance <font color="blue">organizations</font>; and         •  self-insured employee plans</td>
    </tr>
    <tr>
      <td>There is considerable pressure to reduce the cost of bio<font color="blue">technology</font> and     <font color="blue"><font color="blue">pharmaceutical</font> products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font>from <font color="blue"><font color="blue">government</font> agencies</font>, insurers     and large health <font color="blue">organizations</font> may become more restricted in the future</td>
    </tr>
    <tr>
      <td>Our     potential  products  represent  a  new  mode of therapy, and while the     cost-benefit ratio of the <font color="blue">products may</font> be favorable, we expect that the     costs  associated  with our <font color="blue">products will</font> be substantial</td>
    </tr>
    <tr>
      <td>Our proposed     products, if <font color="blue">successfully</font> developed, may not be considered cost-<font color="blue">effective</font> by     third-party payers</td>
    </tr>
    <tr>
      <td>Insurance <font color="blue">coverage might</font> not be provided by third-party     payers at all or may be <font color="blue">provided only</font> after substantial delay</td>
    </tr>
    <tr>
      <td>Even if such     coverage is provided, the approved third-party <font color="blue">payment amounts</font> might not be     sufficient to <font color="blue">permit widespread acceptance</font> of our products</td>
    </tr>
    <tr>
      <td>The <font color="blue">continuing efforts</font> of <font color="blue"><font color="blue">government</font>al</font> and third-party payers to contain or     reduce the costs of <font color="blue">healthcare may impair</font> our <font color="blue">future revenues</font> and     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>The pricing of our <font color="blue"><font color="blue">future products</font> may</font> be influenced in part by     <font color="blue"><font color="blue">government</font> controls</font></td>
    </tr>
    <tr>
      <td>For example, in certain foreign markets, pricing or     <font color="blue">profitability</font> of prescription <font color="blue">pharmaceutical</font>s is subject to <font color="blue">government</font>     control</td>
    </tr>
    <tr>
      <td>In the United States, there have been, and we expect that there     <font color="blue">will continue</font> to be, a number of                                         28       _________________________________________________________________    [81]Table of <font color="blue">Contents       </font>federal and state proposals to implement more <font color="blue">rigorous provisions</font> relating     to <font color="blue">government</font> payment levels</td>
    </tr>
    <tr>
      <td>While we <font color="blue">cannot predict</font> whether the <font color="blue">government</font>     will adopt any <font color="blue">such legislative</font> or <font color="blue">regulatory</font> proposals, the <font color="blue">announcement</font> or     adoption of these <font color="blue">proposals could</font> have a material adverse effect on our     business, results of <font color="blue">operations</font>, <font color="blue">financial condition</font> and <font color="blue">cash flow</font></td>
    </tr>
  </tbody>
</table>